Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- LIXTE Biotechnology Holdings, a clinical-stage oncology company known for its LB-100 cancer compound, has entered a definitive agreement to acquire NOMAD Transportable Power Systems and exit the biotech business entirely. - The company plans to rename itself NOMAD Power Solutions and reposition as a deployable, utility-grade battery energy storage platform addressing the electricity shortage constraining AI data-center growth. - NOMAD reports approximately 175% revenue growth in 2025, with management projecting roughly 135% in 2026 and more than 285% in 2027, though these figures remain unaudited management projections. - The North American Electric Reliability Corporation projects summer peak demand will rise by 224 gigawatts over the next decade, underscoring the systemic grid constraints driving demand for rapid-deployment power solutions.
- Lixte Biotechnology Holdings amended its collaboration with the Netherlands Cancer Institute and Oncode Institute, focusing on LB-100 in cancer treatment. - The amendment temporarily pauses study activities until a Phase 1b trial combining LB-100 with a WEE1 inhibitor for metastatic colorectal cancer begins. - The collaboration will resume upon the first patient being dosed, with a reduced annual budget of €100,000 for one year. - The aim is to analyze translational data from patient samples in clinical trials to enhance understanding of LB-100's effects.
- Lixte Biotechnology secured a Nasdaq extension until February 18, 2025, to meet the minimum stockholders' equity requirement of $2.5 million. - The company plans to regain compliance through registered equity offerings, supported by a recent $4 million capital-raising initiative. - Lixte's cancer drug, LB-100, will be evaluated in a clinical trial at the Netherlands Cancer Institute for metastatic colon cancer in combination with atezolizumab. - Recent financial data indicates Lixte holds more cash than debt, but profitability remains a challenge, underscoring the urgency of equity-raising efforts.
- Lixte Biotechnology received a Nasdaq notice for failing to meet the minimum stockholders' equity requirement of $2.5 million. - The company intends to submit a plan within 45 days to regain compliance and potentially receive a 180-day extension. - Lixte is conducting a clinical trial with the Netherlands Cancer Institute, testing LB-100 with Roche's atezolizumab for metastatic colon cancer. - Recent changes in director compensation policy shift from cash payments to equity-based remuneration to preserve cash.
- Researchers are initiating a clinical trial using a 'paradoxical intervention' strategy to treat advanced colorectal cancer by overstimulating oncogenic signaling. - The approach involves LB-100, a PP2A inhibitor, to stress cancer cells, followed by adavosertib, a WEE1 inhibitor, to prevent DNA damage repair. - Preclinical studies in mice showed that this drug combination effectively prevented tumor growth by forcing cancer cells to behave like healthy cells to survive. - This innovative method may lead to new cancer therapies by targeting the fundamental differences between cancer and normal cells, potentially reducing toxic side effects.
- Lixte Biotechnology partners with the Netherlands Cancer Institute to evaluate LB-100 in metastatic colon cancer patients. - The clinical trial will combine LB-100 with atezolizumab, a PD-L1 inhibitor, to enhance the immune response against cancer cells. - Lixte will supply LB-100, while Roche will provide atezolizumab and fund the trial, with no clinical costs for Lixte. - The trial includes a dose escalation phase followed by clinical activity and safety assessment in up to 37 patients over 24 months.
- Lixte Biotechnology is advancing LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, for multiple cancer indications including soft tissue sarcoma and glioblastoma multiforme. - The drug candidate, administered both intravenously and orally, is designed to work synergistically with standard cancer treatments including chemotherapy, radiation, and immune checkpoint blockers. - LB-100, a synthetic derivative of cantharidin, demonstrates significant anti-cancer activity with minimal toxicity across various solid tumors and hematological malignancies.
